Polymeric nanoparticles for a localized
- 1Department of Life Sciences, University of Trieste, 34127 Trieste, Italy; Corresponding author: Frea Maddalena, Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
- 2Department of Life Sciences, University of Trieste, 34127 Trieste, Italy
- 3Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, 33081 Aviano, Italy
Abstract
The local production of therapeutic proteins has generated considerable interest in the research community as a strategy to overcome the challenges associated with conventional protein-based therapies, such as high costs, the inconvenience of repeated administrations, and unwanted side effects. This review explores the potential of targeted polymeric nanoparticles that carry nucleic acids to induce controlled, localized production of therapeutic antibodies. Polymeric nanoparticles are analyzed on the basis of four key components: (1) the polymer matrix, including cationic, non-cationic, lipid-polymer hybrid, and cyclodextrin-based systems; (2) the genetic payload designed for antibody production; (3) linker chemistry, ranging from standard covalent bonds to stimuli-responsive or non-covalent bonds; and (4) potential targeting tools such as antibodies/fragments, peptides, or aptamers, for identifying target cells. By combining gene therapy with nanomedicine, these particles reduce immune responses and show great promise for treating cancer, infections, and autoimmune diseases. To this end, their structure is discussed in relation to the therapeutic antibody’s mechanism of action and to their in vivo validation as a next-generation platform for antibody-based immunotherapies.
Related
- Molecular design and therapeutic applications of polymeric nanoparticles for drug delivery: A comprehensive review
- Surface-Engineered 3D-Printed Polymeric Flat-Panel Photoreactors with P25 TiO2 Nanoparticles for Photocatalytic Hydrogen Evolution
- Contrast-Engineered Polymeric Nanoparticles Enable Multicomponent SAXS Imaging in Soft Matter
- Phyto-Lipid Polymeric Hybrid Nanoparticles Enable Anti-inflammatory Immunomodulation through Corona-Mediated Cytokine Sequestration
- Temperature-Dependent Localized Surface Plasmon Resonance in Gallium Nanoparticles
BibTeX
@article{frea2026polymeric,
title = {{Polymeric nanoparticles for a localized}},
author = {Maddalena Frea and Paolo Durigutto and Michele Dal Bo and Paolo Macor},
journal = {Molecular Therapy: Nucleic Acids},
year = {2026},
month = nov,
doi = {10.1016/j.omtn.2026.103149},
url = {https://doi.org/10.1016/j.omtn.2026.103149},
note = {CC BY},
}
RIS
TY - JOUR
TI - Polymeric nanoparticles for a localized
AU - Maddalena Frea
AU - Paolo Durigutto
AU - Michele Dal Bo
AU - Paolo Macor
PY - 2026
DA - 2026/11/07
JO - Molecular Therapy: Nucleic Acids
DO - 10.1016/j.omtn.2026.103149
UR - https://doi.org/10.1016/j.omtn.2026.103149
AB - The local production of therapeutic proteins has generated considerable interest in the research community as a strategy to overcome the challenges associated with conventional protein-based therapies, such as high costs, the inconvenience of repeated administrations, and unwanted side effects. This review explores the potential of targeted polymeric nanoparticles that carry nucleic acids to induce controlled, localized production of therapeutic antibodies. Polymeric nanoparticles are analyzed on the basis of four key components: (1) the polymer matrix, including cationic, non-cationic, lipid-polymer hybrid, and cyclodextrin-based systems; (2) the genetic payload designed for antibody production; (3) linker chemistry, ranging from standard covalent bonds to stimuli-responsive or non-covalent bonds; and (4) potential targeting tools such as antibodies/fragments, peptides, or aptamers, for identifying target cells. By combining gene therapy with nanomedicine, these particles reduce immune responses and show great promise for treating cancer, infections, and autoimmune diseases. To this end, their structure is discussed in relation to the therapeutic antibody’s mechanism of action and to their in vivo validation as a next-generation platform for antibody-based immunotherapies.
SN - 2162-2531
ER -